GenSight Biologics

GenSight Biologics occupies a specialized position in retinal gene therapy, concentrating on severe and rare vision disorders rather than pursuing a broad genetic-medicine portfolio. Its lead program, GS010/LUMEVOQ, uses an AAV2 vector to deliver a functional ND4 gene and address mitochondrial dysfunction in Leber hereditary optic neuropathy. That focus differentiates GenSight from broader ophthalmic gene-therapy developers such as 4D Molecular Therapeutics and MeiraGTx, while its optogenetic GS030 program creates a second technology path for patients with surviving retinal ganglion cells. The company also competes indirectly with established retinal gene-therapy approaches associated with Spark Therapeutics and other AAV developers, although the clinical targets and development stages differ. GenSight’s distinctive assets are its Mitochondrial Targeting Sequence platform, optogenetics program and emphasis on a single intravitreal administration per eye. The company is public and has reported 22 funding rounds, but its disclosed employee range of 11 to 50 and current valuation of €27 million indicate a relatively small operating scale. The available comparable-company list is limited and contains duplicate GenSight entries, so direct benchmarking of commercial position, headcount and pipeline maturity remains constrained.

GenSight’s trajectory shows a transition from venture-backed platform development to public-company financing, clinical execution and controlled commercialization preparation. Founded in 2012, it went public on Jul 13, 2016 and has recorded 22 funding rounds, with structured funding totaling $284.1 million. The recent financing cadence is notable: post-IPO equity raises were recorded between Feb 8, 2024 and Mar 10, 2026, including approximately $1.97 million in the latest round. Rather than rapid headcount growth, the company has emphasized management transition and cost management. Laurence Rodriguez became CEO in December 2023, while regulatory leadership expanded in February 2026 with Fang Li and Sabrina Chekroun. French compassionate-use authorization and Israeli early-access authorization for LUMEVOQ were announced on Dec 22, 2025, followed by first-patient treatment in the REVISE study on Feb 10, 2026. A manufacturing partnership with Catalent reached an upstream-process transfer milestone on Jun 26, 2025, supporting potential yield and analytical improvements. The trajectory therefore reflects incremental de-risking of a lead gene-therapy asset, supported by early-access revenue potential and repeated equity financing, but also continued dependence on regulatory progress and liquidity discipline.